http://dx.doi.org/10.15344/2393-8498/2015/114
Abstract
Background: Bacillary dysentery (Shigellosis) is an intestinal infection caused by the Shigella spp is potentially contagious for human health. The significant hallmark of Shigellosis is the bloody diarrhea particularly in developing countries with poor quality hygiene. Shigella species are accountable for a morbidity as well as mortality and poses threat to kids younger than five years and elder people with an undermined immune system. However, Shigella quickly spread in place having suffocated crowded dwellings and is transmitted directly by fecal material or through contaminated food or water.
Methods: A comparative study was undertaken to determine the efficacy of ShigelDysent (Test drug) in comparison with Ciprofloxacin (Control drug) in alleviating the clinical sign and symptoms of Shigellosis. The research was undertaken among age group 25-45 years in 2010-2013. Shigellosis was recorded in 250 patients dividing them into two parallel arm groups; 125 for test and 125 for control group each without consideration of the socio-economic status.
Results: Results showed that the medicinal plant coded formulation ShigelDysent exhibit significant (p< 0.029) efficacy in relieving the clinical features for sign and symptoms of Shigellosis comparable with that of standard drug Ciprofloxacin.
Conclusion: ShigelDysent is effective in the in the treatment and management of Shigellosis. However further studies on large scale are suggested to find out the pharmacological action of ShigelDysent.